This Article Full Text (PDF) All Versions of this Article: 0269881108091879v1 23/7/805    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Messer, T Articles by Schmauss, M PubMed PubMed Citation Articles by Messer, T Articles by Schmauss, M Social Bookmarking                         What's this?

Long-term treatment with flupentixol results of a post-marketing surveillance study

Clinic for Psychiatry and Psychotherapy, Regional Hospital Augsburg, Germany t.messer{at}bkh-augsburg.de

T Glaser

Bayer Vital GmbH, Leverkusen, Germany

H Landen

Bayer Vital GmbH, Leverkusen, Germany

M Schmauss

Clinic for Psychiatry and Psychotherapy, Regional Hospital Augsburg, Germany

Abstract

Schizophrenia is one of the most expensive illnesses. Antipsychotics are an essential component of the acute and preventative treatment of this illness, and long-term treatment is necessary to decrease the risk of psychotic relapse. The efficacy and tolerability of flupentixol was evaluated in a post-marketing surveillance study (PMS) in schizophrenic patients receiving long-term treatment in routine clinical practice. Psychiatrists in office practice treated patients for approximately 10 weeks, with a subsequent follow-up period of up to 18 months. We here report on the follow-up period in 128 patients. The benefit for schizophrenic patients increased with the treatment duration of flupentixol as documented by the Clinical Global Impression (CGI). Subjective quality of life improved during the first study period, and this remained stable in the follow-up period. No increase in body weight was observed during the study. The relapse rate was much lower than in other studies. Anticholinergic medication was necessary for 22.7% of the patients at any time. More than 70% of the psychiatrists involved evaluated the treatment as very good or good. The results of this study suggest that flupentixol is a potent and safe antipsychotic for the long-term treatment of schizophrenia in routine clinical practice.

Key Words: flupentixol • schizophrenia • antipsychotics • neuroleptics • treatment • tolerability

This version was published on September 1, 2009

Journal of Psychopharmacology, Vol. 23, No. 7, 805-813 (2009)
DOI: 10.1177/0269881108091879


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?